More Articles


Australia’s field force: evolving on fast forward

Lucy Fulford, (Sep 16, 2020)

Australian pharma’s field force roles are changing fast and the new digital-first environment is driving a need for new approaches and new skillsets
Patients and Medical

The future of Medical Affairs: A virtual Q&A with Charlotte Kremer

Andrew Stone, (Sep 10, 2020)

The Astellas head of medical affairs follows up with answers to questions during her virtual keynote earlier this year
Access and Evidence

Survey results: Accelerating digital transformation during COVID-19

Nicola Davies, (Sep 4, 2020)

View the results of a survey of over 1000 pharma executives on the impact COVID-19 has had and will have on their operations

Paying for cell and gene therapy - Is the future already here?

Ulrich Neumann, (Aug 25, 2020)

Multiple novel payment models for CGT are in development but an open and collaborative approach among all healthcare stakeholders is needed if the significant legal and practical barriers are to be overcome
Patients and Medical

The future of medical congresses

Katie Osborne, (Aug 18, 2020)

The mega congresses of the past look likely to make way for more virtual, focused and, probably, hybrid physical/digital events

The age of the digital opinion leader

Andrew Stone, (Jul 28, 2020)

Key opinion leaders who evolve into the digital sphere to become digital opinion leaders will gain more reach and influence

Webinars: Engaging at scale now and tomorrow

Nicola Davies, (Jul 21, 2020)

As face-to-face gatherings became impossible, webinars have emerged as a key way to engage for those who can master the format
Patients and Medical

Patient centricity: Mind the capacity gap

Lucy Fulford, (Jul 21, 2020)

If pharma wants patients and patient groups capable of working with it at every stage of the drug development process it must listen to, and contribute to training and funding them
Patients and Medical

What patients need right now

Andrew Stone, (Jul 7, 2020)

In the face of massive patient need, there’s plenty pharma can do to help. The crisis is also an opportunity for it to transform the way it works with patients.

The key to digital innovation: The human touch

Andrew Stone, (Jun 30, 2020)

Takeda is building on strong stakeholder relationships it has nurtured patiently over time to co-create solutions during COVID-19